1. Introduction {#s0005}
===============

The immune system of individuals infected with human immunodeficiency virus (HIV) is gradually compromised and when untreated ultimately leads to advanced acquired immunodeficiency syndrome (AIDS), making patients vulnerable to opportunistic infections, malignancies, and other pathologies. Several different types of cancer are observed at an increased incidence in HIV-infected persons compared to the general population ([@bb0020; @bb0040]). For example, primary effusion lymphoma (PEL) is a very aggressive non-Hodgkin Lymphoma (NHL) that most regularly appears in patients with major immunodeficiency, primarily in the context of HIV infection and advanced stages of AIDS. PEL is by definition associated with Kaposi\'s sarcoma-associated herpesvirus (KSHV, HHV-8) and most HIV-positive cases also show evidence of Epstein--Barr virus (EBV) infection ([@bb0035]). It originates within major body cavities such as the pleural, peritoneal spaces, or the pericardium. PEL has very poor prognosis with a survival time of two to three months after diagnosis without treatment and only six months with aggressive chemotherapy ([@bb0055]). There is no standard therapy for the treatment of PEL and combination chemotherapy is considered first-line therapy ([@bb0055; @bb0150]). The use of anti-HIV drugs is associated with better prognosis suggesting antiretroviral therapy as part of the supportive treatment ([@bb0190; @bb0025]). Other approaches outside traditional chemotherapy have been investigated, including the addition of anti-herpes therapy such as cidofovir ([@bb0110]) or the use of NF-κB inhibitors ([@bb0160; @bb0005]). Very recently, brentuximab vedotin ([@bb0010]), which is an anti-CD30 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E, and a proteasome-HDAC inhibitor combination ([@bb0015]) have been demonstrated to be effective against PEL. Although patients display response to therapy, remissions are often short-term and current chemotherapy approaches still result in poor outcome ([@bb0145; @bb0150]) warranting investigation of original therapeutic strategies for PEL.

Successful HIV replication relies on different cellular factors and processes, and one such cellular co-factor is XPO1. In fact, the HIV protein Rev was first characterized as the prototype cargo protein substrate for XPO1. Rev highjacks the XPO1-mediated nuclear export pathway to transport the late viral RNA species to the cytoplasm ([@bb0215; @bb0095; @bb0250]). These late RNA species are produced by alternative splicing from a single, full-length proviral transcript and still contain introns. Importantly, effective replication requires the nuclear export and translation of these intron-containing RNAs. Under normal circumstances, intron-containing pre-RNAs are retained in the nucleus by the interaction of splicing factors until they are either spliced to completion or degraded. In order to overcome the nuclear retention of intron-containing RNAs by host cell factors, the early viral gene product Rev forms a multimeric complex on a secondary structured RNA element (the Rev response element, RRE) present in all unspliced and partially spliced viral mRNAs. Hence prior to the onset of splicing, Rev directs their transport to the cytoplasm *via* interaction with XPO1. The nuclear export of these late viral messengers is required for both the expression of late viral genes (*gag*, *pol* and *env*) and packaging of genomic RNA.

As the main effector of nuclear-cytoplasmic transport in cells, XPO1 also exports cargos such as tumor suppressor and growth regulatory proteins. Deregulation of the XPO1-mediated nuclear export can result in uncontrolled cell growth and carcinogenesis ([@bb0155; @bb0295]) and increased expression of XPO1 has been observed in several cancers ([@bb0305; @bb0320; @bb0125; @bb0235]). Several inhibitors of XPO1 exist among which leptomycin B is best known ([@bb0230; @bb0315]). Inhibition of XPO1 restores tumor suppressor function and induces cytotoxicity in cancer cells ([@bb0180; @bb0285]). Another XPO1 inhibitor CBS9106 showed anti-tumor activity in a variety of cancer cell lines and displayed tumor growth suppression in multiple myeloma xenograft ([@bb0265]). However, the effect of XPO1 inhibition on PEL has not been studied. Recently selective inhibitors of the exportin-1 (XPO1) mediated nuclear export (SINE) were found to have great potential against various solid and hematological cancers in *in vitro* as well as *in vivo* models of NHL and other hematological malignancies ([@bb0085; @bb0090; @bb0130; @bb0185; @bb0290; @bb0325; @bb0255; @bb0170]). SINE are orally bioavailable optimized analogues of the *N*-azolylacrylate small-molecule inhibitors affecting XPO1-mediated nuclear export ([@bb0310; @bb0065]). They selectively bind into the hydrophobic cargo-binding pocket of XPO1 and interact covalently with Cys528 of XPO1 through a Michael type addition ([@bb0090; @bb0185; @bb0310; @bb0225]). The lead SINE selinexor (KPT-330) is currently in different Phase 1 and 2 clinical studies for solid and hematological malignancies and early results show that selinexor is well tolerated with clear anti-tumor activity.

As the majority of PEL cases occur in HIV-seropositive patients and the use of antiretroviral therapy appears to be associated with better prognosis, a dual anti-neoplastic and anti-retroviral effect by targeting a common process in both diseases may be beneficial in the treatment of PEL. In this study we demonstrate that inhibition of XPO1 by SINE potently suppresses both HIV and PEL. This combined effect may be clinically relevant in HIV-infected PEL patients and provides the basis for the use of XPO1 inhibitors as an innovative anti-PEL therapeutic approach.

2. Materials and Methods {#s0010}
========================

2.1. Cell Lines and Reagents {#s0025}
----------------------------

PEL cell lines BC-1 ([@bb0045]) (ATCC), BCBL-1 ([@bb0260]) and JSC-1 ([@bb0030]) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and gentamicin (Gibco BRL). HEK293T cells were maintained in DMEM supplemented with 10% fetal bovine serum and gentamicin (Gibco BRL). Cell lines acquired from ATTC were thawed, enlarged and immediately cryopreserved in multiple batches. Cells were thawed from these batches and kept for no longer than 6 months in culture. Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation (Lymphoprep).

2.2. Cell Viability, Cell Cycle and Apoptosis {#s0030}
---------------------------------------------

Cell viability was measured using either MTT assay ([@bb0240]) or the AlexaFluor488 Annexin V-Dead Cell Apoptosis Kit (Life Technologies), and/or the Live--Dead Cell Viability Assay (Life Technologies), using a FACSCanto II flow cytometer (BD Biosciences). Cell cycle analysis was performed using the BD Cycletest PLUS (BD Biosciences) according to the manufacturer instructions. DNA content was determined on a FACSCanto II flow cytometer (BD Biosciences).

2.3. Immunofluorescence Staining {#s0035}
--------------------------------

Cells were treated with 1 μM of compound or solvent (DMSO) for 16 h. Cells were washed in PBS and transferred into a Labtek 8-well chambered coverglass, pretreated with 0.1% (w/v) poly-[l]{.smallcaps}-lysine (Sigma). Cells were allowed to adhere to the slides and carefully washed with PBS. Cells were then fixed with 4% aqueous PFA solution, washed and permeabilized (0.1% Triton X-100 in PBS). They were then further treated for immunofluorescence staining according to standard procedures. Cell nuclei were counterstained using DAPI. Employed antibodies were mouse monoclonal anti-p53 (DO-1) (sc-126) and, rabbit anti-p73 (H-79) (sc-7957) at 1:100 dilution (both from Santa Cruz Biotechnology) at a 1:100 dilution, and secondary Alexa Fluor® 488 goat anti-mouse or goat ant-rabbit antibody (A11001, A11008, resp., Molecular Probes). Images were collected with a Leica TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany), employing a HCX PL APO 63 × (NA 1.2) water immersion objective.

2.4. Western Blot Analysis {#s0040}
--------------------------

Western blot was performed according to standard protocol. Briefly, cells were seeded at 0.5 × 10^6^ cells/ml in 24 well plates containing RPMI with 10% FCS. Compounds were added and incubated for 16 h, washed with ice-cold phosphate buffered saline (PBS) and lysed in lysis buffer (50 mM Tris--HCl, 50 mM NaCl, 5 mM MgCl~2~, 0.5% Triton and 1 × Halt protease inhibitor cocktail (Thermo Scientific) for 1 h on ice (20 × 10^6^ cells/ml). Lysates were cleared by centrifugation and the soluble supernatant was collected. Protein lysates were resolved by SDS-PAGE and transferred to Amersham Hybond™-P membrane (GE Healthcare). The membranes were incubated for 1 h at room temperature in blocking buffer (5% nonfat dry milk in PBS containing 0.05% Tween 20) and subsequently for 12 h at 4 °C in blocking buffer with primary antibodies raised against PARP-1 (sc-8007, Santa Cruz Biotechnology) caspase-3 (sc-271028, Santa Cruz Biotechnology), p53 (sc-126, Santa Cruz Biotechnology), XPO1 (ab24189, Abcam) and α-Tubulin (sc-5286, Santa Cruz Biotechnology). After washing, the membranes were incubated with anti-mouse (sc-2005, Santa Cruz Biotechnology) or anti-rabbit (ab97064, Abcam) horseradish peroxidase-conjugated secondary antibody in blocking buffer for 20 min at room temperature. Subsequently the membranes were washed extensively and detected by addition of chemiluminescent substrate (Thermo Fisher Scientific).

2.5. Anti-HIV Testing {#s0045}
---------------------

PBMCs were isolated by density centrifugation (Lymphoprep; Axis-Shield, PoC AS, Oslo, Norway) and stimulated with 2 μg/ml phytohemagglutinin (PHA) (Sigma) for 3 days. Then the cells were washed three times with PBS and viral infections were performed as described by [@bb0135]. The infected cells were cultured further in the presence of 25 U/ml of IL-2 for 4 days to allow virus spreading. Subsequently, supernatant was removed, cells were washed with PBS and incubated in the presence of varying concentrations of drugs. Supernatant was collected the next day in order to assess virus production by quantifying the virus-associated core antigen (p24) by ELISA (GE Healthcare). Cytotoxicity was measured in parallel on mock-infected cells using flow cytometry.

2.6. Time-of-addition Experiments {#s0050}
---------------------------------

Time-of-addition experiments were performed as described ([@bb0080]). Briefly, C8166 cells were infected with HIV-1 (III~B~) at an m.o.i. of 0.5. Following a 1 h adsorption period cells were distributed in a 96-well tray at 45,000 cells/well and incubated at 37 °C. Test compounds were added at different times (0--24 h) after infection. HIV-1 production was determined at 31 h postinfection *via* a p24 ELISA.

2.7. Northern Blot Analysis {#s0055}
---------------------------

mRNA was extracted using the Oligotex Direct mRNA kit (Qiagen), treated with RNase-free DNase I (Invitrogen), and separated by agarose electrophoresis under denaturing conditions. mRNA was blotted using the NorthernMax-Gly system (Ambion) according to manufacturers manual. The biotin labeled RNA probe spanning exon 7 from the *Bam*HI to the *Bgl*II site (nt 8475 through 9056) of the NL4-3 genome was produced by *in vitro* transcription from T7 primer PCR products.

2.8. CRISPR-Cas9 Genome Editing {#s0060}
-------------------------------

The genome editing was performed as described in [@bb0225]. Briefly, HEK293T cells were transfected with a Cas9 expression construct, the optimized sgRNA construct (both obtained from ToolGen-Labomics) and a 135 base oligonucleotide (IDT) for homologous recombination. The sgRNA targets the *XPO1* sequence: 5′-GGATTATGTGAACAGAAAAGAGG-3′ and the 135 base oligonucleotide consisted of the following sequence: 5′-GCTAAATAAGTATTATGTTGTTACAATAAATAATACAAATTTGTCTTATTTACAGGATCTATTAGGA TTA**TCA**GAACAGAAgcGcGGCAAAGATAATAAAGCTATTATTGCATCAAATATCATGTACATAGTAGG-3′ Bold indicates the Cys528Ser missense mutation, lowercase indicates additional silent mutations to prevent Cas9 mediated cleavage of the mutated allele.

2.9. Microscopy {#s0065}
---------------

Transfected HeLa cells were imaged with a laser scanning SP5 confocal microscope (Leica Microsystems) equipped with a DMI6000B microscope and an AOBS, using a HCX PL APO × 63 (NA 1.2) water immersion objective. Different fluorochromes were detected sequentially using excitation lines of 405 nm (BFP), 488 nm (GFP, YFP) or 561 nm (mRFP). Emission was detected between 410--480 nm (BFP), 493--565 nm (GFP), 500--580 nm (YFP) and 566--670 nm (mRFP).

2.10. Evaluation of NF-κB Activity {#s0070}
----------------------------------

Cells were transfected using the Neon system (Life Technologies) with plasmids expressing the firefly luciferase either driven either by a promotor containing 6 NF-κB binding sites (NF-κB-Luc) or by the control CMV promotor (CMV-Luc) and incubated in the presence of different concentrations of compounds. Next cells were harvested and analyzed for luciferase expression. Signal from NF-κB-Luc reporter was normalized according to the signal from the control CMV-Luc reporter.

2.11. Mouse Xenograft Model {#s0075}
---------------------------

Female NMRI nude mice (4 weeks old) were purchased from Janvier Breeding Center (Le Genest St Isle, France) and maintained in a temperature- and humidity-controlled environment. Mice were injected subcutaneously with 2 × 10^7^ BC-1 cells in 50% Matrigel (BD Biosciences). Treatment *per os* was started after the tumors were established. KPT-330 (20 mg/kg) or vehicle control was administered twice a week for a total of 4 weeks. Tumor volumes were measured with a caliper and calculated according to the formula V = (length × width^2^) / 2. In order to monitor the health of the animals, the mice were weighed once per week. All animal studies were approved by the KU Leuven Ethics Committee for Animal Care and Use. Statistical analysis was performed using ANOVA.

2.12. Statistical Analyses {#s0080}
--------------------------

Data are presented as mean ± SEM. Comparisons were performed by two-tailed paired *t*-test or by ANOVA followed by Bonferroni\'s correction, as adequate. A *P* value \< 0.05 was considered as statistically significant.

3. Results {#s0015}
==========

3.1. Inhibition of XPO1 Suppresses the Replication of HIV in Primary Cells {#s0085}
--------------------------------------------------------------------------

KPT-185 ([Fig. 1](#f0005){ref-type="fig"}A) is a SINE compound that effectively and selectively inhibits the XPO1-mediated nuclear export ([@bb0225]). To evaluate the effect of inhibition on HIV replication, we determined the anti-HIV activity of KPT-185 in primary human peripheral blood mononuclear cells (PBMCs). Upon treatment of HIV-infected PBMCs for 24 h, KPT-185 displayed potent anti-HIV activity in these primary cells (IC~50~: 40 ± 14 nM) ([Fig. 1](#f0005){ref-type="fig"}B). The compound proved active against viral strains using the CXCR4 or CCR5 chemokine co-receptor while it caused cytotoxic effects only at concentrations that were 850-fold higher than the active concentration (CC~50~: 34 ± 13 μM) as measured by calcein AM staining and confirmed by annexin-PI flow cytometry. Furthermore, KPT-185 also suppressed the replication of a clinical isolate (MDR) that was resistant to nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI) as well as clinical virus isolates from different subtypes of group M ([Table 1](#t0005){ref-type="table"}). These results illustrate the broad-spectrum anti-HIV activity of XPO1 inhibition.

3.2. KPT-185 Suppresses HIV Replication by Targeting the Nuclear Export of Rev-dependent Viral mRNA {#s0090}
---------------------------------------------------------------------------------------------------

To ascertain that the mechanism of the observed inhibition of virus replication by KPT-185 is caused by the inhibition of XPO1 function we engaged in detailed mechanism of action studies. First we performed a time-of-addition experiment ([@bb0080]). This experiment is based on the fact that HIV undergoes several well-established successive chronological processes and for almost each of these processes well-characterized inhibitors exist. In this experiment, in which a single replication cycle of the virus is followed, it is determined how long the addition of a drug can be postponed before it loses its anti-HIV activity. Comparing the time-of-addition profile of an investigational drug to that of classical anti-HIV inhibitors with known target of action, narrows down the time frame of action and thus the possible target of action of the investigational drug. For instance, an inhibitor interfering with the reverse transcription process will suppress virus replication when added at a time point before the fulfillment of the reverse transcription process (*i.e.* approximately 4--5 h post infection), but not if added at a time point after the reverse transcription process has already occurred ([Fig. 2](#f0010){ref-type="fig"}A). In this experiment, KPT-185 shows the same profile as the viral transcription inhibitor WP7-5, suggesting that KPT-185 interferes with a process coinciding with viral transcription. Of note, it has been suggested that the nuclear export of late HIV RNAs occurs co-transcriptionally ([@bb0220]).

To narrow down the mechanism by which KPT-185 inhibits HIV replication we analyzed the expression levels of the different viral RNA species. Therefore, we visualized the viral mRNA species isolated from HIV-1 infected PBMCs treated with KPT-185 by northern blot ([Fig. 2](#f0010){ref-type="fig"}B). A clear reduction of the late viral mRNA species (9 kb: unspliced and 4 kb: singly spliced) that are dependent on the Rev-XPO1-mediated transport for their expression ([@bb0215]) was observed, demonstrating that KPT-185 suppresses the expression of these mRNA forms. This is in contrast to the early RNA forms (2 kb: fully spliced) that are expressed independently of XPO1, and were even increased in conditions where the late RNA forms were reduced. We assume this observation is caused by retention of the viral intron-containing RNA in the nucleus eventually leading to degradation or splicing into fully spliced RNA forms. Although we have used whole cell lysate and did not separate between cytoplasmic and nuclear fraction the observed specific reduction of intron-containing RNA species is considered to be caused by inhibition of their nuclear export. This is in agreement with earlier published northern blot experiments with a mutant HIV-1 strain (fB) that is defective in the Rev-XPO1-mediated nuclear RNA export. In whole cell lysates of cells transfected with this mutant, the amount of unspliced genomic length mRNA was also reduced while the fully spliced 2 kb viral mRNA species augmented ([@bb0105]). In addition, the increase of fully spliced 2 kb viral transcripts upon treatment with KPT-185 suggests that the compound does not inhibit the transcription process as transcription is supposed to be uniform for both the early and late viral RNA forms. Altogether these observations suggest that KPT-185 specifically inhibits the Rev-XPO1-mediated export of the late viral RNA species from the nucleus to the cytoplasm.

To further support this conclusion we engineered a viral-like mRNA that can be tagged with GFP through the bacteriophage MS2 coat protein ([@bb0275]) in order to visualize the RNA inside the cell. In cells co-expressing the viral-like intron-containing mRNA (LTR-gag-24xMS2-RRE) together with the MS2-GFP protein, individual mRNA molecules could be observed in the nucleus ([Fig. 2](#f0010){ref-type="fig"}c). In the presence of the viral Rev protein, which directs transport of viral intron-containing RNA to the cytoplasm through the interaction with the XPO1 protein, the tagged viral-like RNA translocates to the cytoplasm. Upon treatment with KPT-185, this RNA is trapped in the nucleus, demonstrating that its nuclear export is blocked by the compound ([Fig. 2](#f0010){ref-type="fig"}c). Altogether, these results show that indeed KPT-185 inhibits the transport of intron-containing HIV RNA to the cytoplasm and traps it in the nucleus. Correspondingly, KPT-185 inhibited the nuclear export of the viral protein Rev ([Fig. 2](#f0010){ref-type="fig"}d). Therefore we used a Rev mutant protein (RevM5) that is fused to GFP that predominantly confines to the cytoplasm but it is still functional in shuttling between nucleus and cytoplasm ([@bb0070; @bb0210]). Knockdown of XPO1 expression resulted in nuclear accumulation of RevM5-GFP ([Fig. 2](#f0010){ref-type="fig"}d) demonstrating the XPO1-dependent cytoplasmic localization of RevM5-GFP. Similarly, in KPT-185 treated cells the RevM5-GFP relocated to the nucleus within 3 h indicating that its XPO1-dependent export from the nucleus is inhibited ([Fig. 2](#f0010){ref-type="fig"}d, Supplementary Figure S1, and [Movie S1](#ec0010){ref-type="supplementary-material"}).

3.3. KPT-185 Disrupts the Rev-XPO1 Interaction in Cells {#s0095}
-------------------------------------------------------

We next analyzed the effect of KPT-185 on the XPO1-Rev interaction in cells using a fusion of Rev to the blue fluorescent protein (Rev-BFP) and XPO1 fused to the yellow fluorescent protein (XPO1-YFP) ([Fig. 2](#f0010){ref-type="fig"}e). In agreement with previously published data, when expressed separately, Rev-BFP localized in the nucleoli of the cells whereas XPO1-YFP was found predominantly at the nuclear membrane as well as within the nucleus ([@bb0060; @bb0075]). When both proteins are co-expressed, a significant fraction of XPO1-YFP is found in the Rev-containing nucleoli suggesting interaction between the two proteins. Treatment of cells co-expressing Rev-BFP and XPO1-YFP with 1 μM KPT-185 abolished this Rev-dependent XPO1-YFP nucleolar localization indicating that KPT-185 disrupts the XPO1-Rev interaction inside living cells ([Fig. 2](#f0010){ref-type="fig"}e; also see [Movie S2](#ec0015){ref-type="supplementary-material"}). As a control, XPO1-YFP co-localized only very weakly with the transdominant negative RevM10-BFP mutant (containing mutations in its NES that hampers interaction with XPO1), demonstrating that the observed co-localization with wild-type Rev-BFP is NES-specific (Supplementary Figure S2).

3.4. CRISPR-Cas9 Genome-editing Validates XPO1 as KPT-185\'s Target in HIV Replication {#s0100}
--------------------------------------------------------------------------------------

To further prove that the observed inhibition of the viral replication by KPT-185 is exclusively caused by inhibition of XPO1 and not by off-target or unspecific effects, we generated a HEK293T cell-line expressing the resistant XPO1~C528S~ protein. Mutating the Cys528 in the hydrophobic cargo-binding groove of XPO1 to a serine residue confers resistance to KPT-185 ([@bb0225]). We used CRISPR-Cas9 genome editing in combination with homology directed repair to introduce a single Cys528Ser point mutation in the *XPO1* gene of HEK293T cells. HEK293T cells were transfected with Cas9 endonuclease, a 23-bp guide RNA and a 135 base single stranded oligodeoxynucleotide repair donor template containing the TCA mutant codon to introduce the serine at position 528 in the *XPO1* gene. Single cell derived colonies were analyzed for the mutation in their genomic DNA by Sanger sequencing ([Fig. 3](#f0015){ref-type="fig"}A). A homozygous mutant colony was selected for further experiments. The mutant HEK293T-XPO1~C528S~ cell line or wild-type HEK293T cells were transfected with the HIV-1 molecular clone NL4-3 and treated with different concentrations of KPT-185. Twenty-four hours after treatment, culture supernatants were analyzed for the presence of virus ([Fig. 3](#f0015){ref-type="fig"}B). Absolute virus production was about 3 times lower in mutant cells as compared with wild-type cells. KPT-185 suppressed virus production from transfected wild-type HEK239T cells, while it had no effect on virus production from the mutant HEK293T-XPO1~C528S~ cells. These results unambiguously demonstrate that the anti-HIV activity of KPT-185 is exclusively caused by inhibition of XPO1 and confirm that cysteine528 is involved in the mechanism of action of KPT-185.

3.5. XPO1 Inhibition Induces Selective Cytotoxicity, Apoptosis and Cell Cycle Arrest in PEL Cell Lines {#s0105}
------------------------------------------------------------------------------------------------------

KPT-185 has shown promising activity in different types of hematological cancers including NHL. Because PEL is an aggressive NHL with very poor prognosis and typically occurs in HIV-infected individuals we next evaluated the anti-PEL activity of KPT-185. The expression of XPO1 was first examined in PEL cell lines BC-1, BCBL-1, and JSC-1 by immunoblotting. XPO1 was highly overexpressed in these PEL cell lines as compared to normal cells ([Fig. 4](#f0020){ref-type="fig"}A). Therefore, the cytotoxic effect resulting from the inhibition of the XPO1-mediated nuclear protein export by KPT-185 was investigated in these PEL cell lines. PEL cell lines were cultured in the presence of increasing concentrations of compound for 72 h and cell viability was analyzed by MTT reduction. KPT-185 caused significant cytotoxicity in all PEL cell lines at submicromolar concentrations with EC~50~ values around 100 nM while they did not drastically affect PBMCs at much higher concentrations ([Fig. 4](#f0020){ref-type="fig"}B). The inhibitory effect of KPT-185 for PEL cells was confirmed by annexin V-PI staining as early as 24 h after treatment ([Fig. 4](#f0020){ref-type="fig"}C). High levels of annexin V staining at submicromolar concentrations of KPT-185 indicate that cells undergo apoptosis within the same timeframe. This induction of apoptosis in PEL was caspase-dependent as demonstrated by caspase-3 and PARP cleavage ([Fig. 4](#f0020){ref-type="fig"}D). To further examine the effect of KPT-185 on the cell cycle of BC-1, BCBL-1 and JSC-1 cells, cell cycle distribution was determined by DNA PI staining of cells incubated with different concentrations of KPT-185 for 24 h ([Fig. 4](#f0020){ref-type="fig"}E). PEL cells undergo cell cycle arrest in G1 upon treatment with KPT-185 while the S- and G2/M-phase of proliferating cells decreased. Consistent with the levels of annexin V staining, an increase in subG1 apoptotic cells is also observed and becomes even more pronounced at higher compound concentrations. These results show that KPT-185-mediated inhibition of XPO1 induces cell cycle arrest and causes apoptosis in PEL cells.

3.6. KPT-185 Treatment Causes Nuclear Accumulation of p53 Cargo and Affects NF-κB Activity in PEL Cells {#s0110}
-------------------------------------------------------------------------------------------------------

Inhibition of XPO1 is known to result in nuclear accumulation of its cargo proteins such as p53 and IκB ([@bb0185]). Therefore, we first investigated the effect of KPT-185 on p53 tumor suppressor expression and nuclear accumulation. Upon treatment of BC-1, BCBL-1 and JSC-1 cells with KPT-185 we observed a significant accumulation of nuclear p53 in all cell lines as demonstrated by immunofluorescence staining ([Fig. 5](#f0025){ref-type="fig"}A) and western blot ([Fig. 5](#f0025){ref-type="fig"}B). Also nuclear levels of p73 were shown to increase upon KPT-185 treatment, further demonstrating the nuclear accumulation of tumor suppressor cargo proteins (Supplementary Figure S3). The augmentation in nuclear p53 levels was accompanied by an intense p53 response as evidenced by the increase in expression of the p21 target gene ([Fig. 5](#f0025){ref-type="fig"}C). In BCBL-1 cells this response is lower than in BC-1 and JSC-1 cells, which can be explained by the p53 status of the cells; while BC-1 and JSC-1 cells are p53 wild-type, BCBL-1 cells are heterozygous for the M246I mutation ([@bb0245]).

NF-κB is constitutively active in PEL cells and plays a crucial role in their survival ([@bb0100; @bb0165; @bb0160]). Because IκB, the endogenous inhibitor of NF-κB, is also a XPO1 cargo protein we next examined if NF-κB activity could also be affected by KPT-185 treatment. Nuclear trapping of IκB by XPO1 inhibition has been demonstrated to reduce NF-κB activity ([@bb0185; @bb0325]). We therefore analyzed NF-κB activity by measuring the firefly luciferase activity driven by a promotor containing 6 NF-κB binding sites ([Fig. 5](#f0025){ref-type="fig"}D). In untreated conditions the levels of NF-κB activity varied among the 3 cell lines as basal activity of NF-κB was about 10 times higher in BC-1 cells when compared to BCBL-1 or JSC-1 cell lines. Treatment with KPT-185 resulted in reduction in NF-κB-driven luciferase activity. This effect was confirmed by the decrease in the NF-κB target gene XIAP expression ([Fig. 5](#f0025){ref-type="fig"}E). However, increase of nuclear IκB-*α* levels was only observed for BC-1 cells ([Fig. 5](#f0025){ref-type="fig"}F). Altogether, these results demonstrate that KPT-185 can functionally increase the levels of p53 and inactivate NF-κB activity in PEL cells.

3.7. XPO1 Inhibition Suppresses PEL Xenograft Tumors {#s0115}
----------------------------------------------------

To establish the *in vivo* activity to XPO1 inhibition against PEL, we engrafted athymic nude mice with BC-1 cells. Mice with tumor size of approximately 150--200 mm^3^ were treated with either vehicle or XPO1 inhibitor. For these *in vivo* studies KPT-330 (selinexor) was used. It is a chemical derivative of KPT-185 with improved PK and is the clinical candidate SINE which is currently under evaluation in multiple phase 1 and 2 studies in humans. It has been demonstrated that both KPT-330 and KPT-185 display the same drug-target interaction profile ([@bb0225]). Treatment with 20 mg/kg KPT-330 only twice a week led to a significant suppression of the BC-1 PEL growth *in vivo* while it had no effect on body weight ([Fig. 6](#f0030){ref-type="fig"}). However, after 4 weeks of treatment in some mice tumors started to grow. Therefore, the tumors from placebo and KPT-330 treated mice were histologicaly examined at 4 weeks post-treatment ([Fig. 6](#f0030){ref-type="fig"}C). In both groups, tumors with a volume ≥ 1000 mm^3^ presented areas ≥ 25 mitosis/mm^2^ (range 26--74 mitosis/mm^2^) and \< 5% p53^+^ cells. Tumors of a smaller size from KPT-330 treated mice presented only areas of 1 mitosis/mm^2^ and \> 10% p53^+^ cells.

4. Discussion {#s0020}
=============

Once in advanced stage of immune deficiency, patients infected with HIV have an increased risk of cancer development. For example primary effusion lymphoma (PEL) is a high-grade non-Hodgkin\'s lymphoma of B-cell origin that is predominantly found in HIV-seropositive individuals ([@bb0120]). Here we show that KPT-185, a member of the SINE class of compounds that are highly selective inhibitors of XPO1 ([@bb0185; @bb0225]) exerts a dual anti-HIV and anti-PEL activity. KPT-185 potently suppresses HIV-1 replication in primary cells at nanomolar concentrations, which are far below concentrations at which cellular toxicity is reached, resulting in a favorable therapeutic index (selectivity index ≈ 850). Importantly, the dose--response curve ([Fig. 1](#f0005){ref-type="fig"}B) displays a steep slope, which is a major determinant for inhibitory potential and in general correlates with good clinical outcome ([@bb0280]). Genome editing using CRISPR-Cas9 in combination with homology directed repair allowed us to generate a homozygous cell line expressing mutant XPO1 containing the Cys to Ser mutation at position 528. This mutation confers resistance to KPT-185 ([@bb0225]). The mutant cell line supported HIV replication indicating that the Cys residue is not essential for viral replication. This mutant cell line allowed us to demonstrate that KPT-185 suppresses HIV replication by directly and specifically targeting the XPO1 mediated nuclear export and not by off target effects. Although, interfering with a host factor is anticipated to elicit cytotoxicity, KPT-185 displays a large therapeutic window; in addition several phase 1 studies in human have revealed a tolerability profile of this class of XPO1 inhibitors *in vivo*; albeit, at doses relevant to cancer growth inhibition. Our data suggest that lower concentrations of SINE may be sufficient to block HIV replication and therefore may limit side effects. Furthermore, in terms of viral resistance selection, which remains a concern in anti-HIV therapy, it is believed that targeting a viral-host interaction may result in a slower or no selection of escape mutants as compared to targeting the viral enzymatic functions. This is because host proteins essential for viral replication, cannot be influenced by viral evolution while any adaptation in the virus that could result in drug resistance is constrained by its interaction with the cellular co-factor. Also, the tight RNA quality control mechanism of the cell that does not allow intron-containing mRNAs to reach the cytoplasm will hamper the use of escape routes for the virus to this new class of inhibitors. A very slow or no generation of escape mutants towards SINE could therefore be reasonably expected. This class of drugs might therefore provide benefit as second-line therapy in patients with multidrug resistant virus. In addition, XPO1 inhibition displays potent anti-PEL activity both *in vitro* and *in vivo* ([Figs. 4 and 6](#f0020 f0030){ref-type="fig"}). All PEL cell lines tested were sensitive to SINE irrespective on whether they are transformed with KSHV alone (BCBL-1) or with both KSHV and EBV (BC-1, JSC-1), illustrating the broad anti-tumor potential of XPO1 inhibitors. PEL are protected from apoptosis caused by anomalous activation of several signaling pathways that promote survival ([@bb0165; @bb0300]), including deregulation of p53 and NF-κB. Reactivation of p53 by Nutlin-3a in KSHV-transformed lymphoma cells has been described to induce massive induction of apoptosis ([@bb0270]) and inhibition of NF-κB down-regulates specific anti-apoptosis, signaling, and growth-related genes and induces apoptosis ([@bb0165; @bb0160]). XPO1 inhibition using LMB or CBS9106 has been found to affect NF-κB activation in multiple myeloma cells ([@bb0265]). Our results show that besides triggering a p53 response in PEL cells, XPO1 inhibition by KPT-185 results also in a decrease in NF-κB activity. In BC-1 cells, this decrease is correlated with the nuclear accumulation of IκB. IκB is an endogenous inhibitor NF-κB and a cargo of XPO1. However, in the other two cell lines nuclear accumulation IκB was not observed, suggesting other mechanisms for inhibition of NF-κB in these cell lines. This difference between the cell lines could be related to the presence of latent EBV gene expression in the cells as BCBL-1 is negative for EBV and JSC-1 has low expression of those genes ([@bb0030]). Nevertheless, inhibition of XPO1 by KPT-185 simultaneously triggers different molecular pathways that synergize to initiate apoptosis in all three PEL cell lines and suppresses BC-1 xenograft growth *in vivo*. Although at 4 weeks after treatment tumor progression is observed in some treated animals. A first histological inspection of these tumors did not reveal a difference with untreated tumors in terms of mitosis events/mm^2^ and % p53^+^ cells, in contrast to the smaller tumors observed in other treated animals. A more elaborate examination may be required to find the basis for their progression. Note that in our experimental set up animals were treated only twice a week with 20 mg/kg suggesting more frequent dosing or higher treatment doses or a combination of both may improve the response.

Our results are in agreement with earlier studies in acute myeloid leukemia where p53 has been found a major determinant of XPO1-inhibition-induced apoptosis by KPT-185 ([@bb0170]). In addition, in chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma XPO1 inhibition by SINE blocks NF-κB activity ([@bb0185; @bb0085; @bb0090]) and down-regulates NF-κB target genes ([@bb0185]) by increasing nuclear levels of IκB. NF-κB is implicated also in survival and drug resistance in multiple myeloma ([@bb0115]) and other tumors and SINE compounds have demonstrated promising activity in these resistant hematological malignancies. Moreover, studies in chronic lymphocytic leukemia and multiple myeloma demonstrated the inhibitory activity of KPT-185 on the production of the inflammatory cytokines such as IL-6 ([@bb0185]), which is also important for the persistence of PEL ([@bb0140]).

Several studies have revealed the tolerability profile of SINE *in vivo* ([@bb0090; @bb0185; @bb0325; @bb0200]). Most importantly, the clinical candidate SINE selinexor (KPT-330) is yet in several phase 1 and 2 trials in human for advanced malignancies (clinicaltrials.gov) and demonstrated high response rates as single agent in trials for heavily pretreated relapsed and refractory hematological and solid tumor malignancies ([@bb0175; @bb0050]). Importantly, the demonstrated *in vivo* efficacy of SINE against hematological tumors indicates that the drug is active in host cells and/or reservoirs of HIV. Although anti-HIV activity of SINE in animal models remains to be directly demonstrated, our *in vitro* results together with the demonstrated *in vivo* activity of SINE in hematological tumors provide strong evidence for *in vivo* anti-HIV effectiveness. Furthermore, SINE might have the potential of successfully targeting HIV persistence. In patients treated with combination antiretroviral therapy, infected cells can persist for a long time and are an important obstacle for curing HIV infection. Importantly it was recently demonstrated that in many cases these persistently infected cells expand from a single clone as a result of integration in genes involved in controlling cell growth and division which the survival and expansion of the infected cells ([@bb0205]). Therefore, to successfully target HIV persistence with the aim of realizing a potential cure, it will be important to suppress both viral replication as well as to inhibit the expansion of infected cells.

This study defines XPO1 inhibition as a potential treatment strategy for PEL, especially in the setting of HIV-infected individuals. Inhibition of XPO1 not only targets multiple signaling pathways that are deregulated in PEL but also simultaneously inhibits the replication of HIV. Consequently, one single agent with a dual role in inhibiting both PEL progression and HIV replication represents an innovative approach and opens interesting new opportunities for PEL therapy. This could be especially beneficial given that antiretroviral therapy correlates with a better prognosis for PEL ([@bb0025; @bb0190; @bb0195]). Moreover, when treating PEL in HIV-infected patients the risk of drug interactions between anti-cancer agents and antiretroviral drugs exists. Small-molecule XPO1 inhibitors thus represent a promising new class of molecules for the treatment of PEL. Our findings therefore provide a strong rationale for using clinical XPO1 small-molecule inhibitors in combined HIV/PEL therapy and potentially other AIDS-related malignancies and other virus-related tumors.

The following are the supplementary data related to this article.Supplementary figures.Movie S1Time‐lapse movie of inhibition of XPO1-dependent nuclear export of RevM5-GFP. HeLa cells expressing RevM5-GFP were treated with 1 μM KPT‐185 and imaged over time. RevM5‐GFP shuttles between the nucleus and cytoplasm using cellular import and export mechanisms, but under steady state conditions and before addition of compound, RevM5GFP localizes predominantly in the cytoplasm; upon treatment with KPT‐185 the accumulation of RevM5-GFP can be observed as a result of inhibition of the XPO1‐dependent nuclear export of the protein, while its import is unaffected.Movie S2Time‐lapse movie of inhibition of XPO1‐Rev interaction in living cells. Cells co‐expressing Rev‐GFP and XPO1‐mRFP were treated with 1 μM KPT‐185 and imaged over time. Before addition of compound, XPO1‐mRFP co‐localizes with Rev‐GFP cargo in the nucleoli of the cell resulting in a yellow color; upon treatment with KPT‐185 the Rev‐GFP/XPO1‐mRFP interaction is disrupted and XPO1‐mRFP detaches from its Rev‐GFP cargo. Unbound XPO1‐mRFP is found throughout the nucleus and at the nuclear envelope.
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![Structure and anti-HIV activity of KPT-185.\
(A) Structure of KPT-185.\
(B) Activity of KPT-185 against HIV-1 CXCR4- (III~B~) and CCR5- (BaL) using virus and a multidrug resistant clinical isolate (MDR) in primary peripheral blood lymphocytes. Virus-infected PBMCs were washed 4 days after infection to remove virus in the supernatant and were subsequently incubated with different concentrations of KPT-185 for 1 day. Virus production was analyzed by monitoring the virus-associated p24 core protein in the supernatant by ELISA. Cellular toxicity was measured in parallel using calcein AM live staining and AnnexinV-PI flow cytometry. Error bars represent standard deviations, n = 5.](gr1){#f0005}

![Anti-HIV mechanism of action of KPT-185.\
(A) Time-of-addition experiment. C8166 cells were infected with HIV-1 at time 0 and inhibitors were added at different time points post infection. Virus production was determined by virus associated p24 production in the supernatant at 31 h after infection. Control: mock treated, nevirapine (7.5 μM): reverse transcriptase (RT) inhibitor; L870, 810 (1.6 μM): integrase (IN) inhibitor; WP7-5 (0.32 μM): transcription inhibitor; ritonavir (2.8 μM): protease (PR) inhibitor; KPT-185 (0.125 μM). Representative of data for 2 independent experiments.\
(B) KPT-185 suppresses expression of intron-containing late viral RNA species. Northern blot analysis of the viral mRNA species (fully spliced: 2 kb; partially spliced: 4 kb; unspliced: 9 kb) in PBMCs infected with HIV-1 III~B~ and treated with different concentrations of KPT-185.\
(C) KPT-185 blocks the Rev-XPO1-mediated nuclear export of intron-containing viral RNA. Top: Schematic view of the MS2-tagged Rev-dependent viral-like RNA, pLTR-p57-24xMS2-RRE. Bottom: HeLa cells were co-transfected with plasmids encoding MS2-GFP and Rev-BFP and an RRE containing viral-like RNA construct carrying 24 MS2 recognition sites, as indicated. After overnight incubation, the sub-cellular localization of fluorescent proteins was visualized by confocal fluorescence microscopy in both GFP and BFP channels. The right column shows overlays of both channels together with DIC (differential interference contrast) images. The insets show a magnification of the 10 μm × 10 μm boxed area in 'glow' color lookup table. Scale bar, 25 μm.\
(D) KPT-185 inhibits the transport of HIV-1 Rev protein. HeLa cells transfected with RevM5-GFP, a mutant of Rev, were analyzed by confocal microscopy. RevM5-GFP is found in the cytoplasm of the cells. Inhibition of nuclear export by siRNA knock down of XPO1 causes the RevM5-GFP protein to accumulate in the nucleus. Similarly, treatment with KPT-185 results in a redistribution of RevM5-GFP to the nucleus. See also Figure S1 and [Movie S1](#ec0010){ref-type="supplementary-material"}.\
(D) KPT-185 inhibits the transport of HIV-1 Rev protein. HeLa cells transfected with RevM5-GFP, a mutant of Rev, were analyzed by confocal microscopy. RevM5-GFP is found in the cytoplasm of the cells. Inhibition of nuclear export by siRNA knock down of XPO1 causes the RevM5-GFP protein to accumulate in the nucleus. Similarly, treatment with KPT-185 results in a redistribution of RevM5-GFP to the nucleus. See also Figure S1 and Movie S1.\
(E) KPT-185 disrupts the XPO1-Rev interaction in living cells. HeLa cells expressing Rev-BFP and/or XPO1-YFP were analyzed by confocal fluorescence microscopy. Rev-BFP is found in the nucleoli of the cells, while XPO1-YFP concentrates at the nuclear membrane. In cells co-expressing both Rev-BFP and XPO1-YFP, XPO1 is redistributed to the Rev-containing nucleoli and co-localizes with Rev-BFP. Two hours after addition of compound the co-localization of wild-type XPO1-YFP with Rev-BFP in the nucleoli was disrupted. See also [Movie S2](#ec0015){ref-type="supplementary-material"}.\
(E) KPT-185 disrupts the XPO1-Rev interaction in living cells. HeLa cells expressing Rev-BFP and/or XPO1-YFP were analyzed by confocal fluorescence microscopy. Rev-BFP is found in the nucleoli of the cells, while XPO1-YFP concentrates at the nuclear membrane. In cells co-expressing both Rev-BFP and XPO1-YFP, XPO1 is redistributed to the Rev-containing nucleoli and co-localizes with Rev-BFP. Two hours after addition of compound the co-localization of wild-type XPO1-YFP with Rev-BFP in the nucleoli was disrupted. See also Movie S2.](gr2){#f0010}

![KPT-185 does not inhibit viral production in CRISPR-Cas9 genome-edited cells expressing the resistant XPO1~C258S~ mutant protein.\
(A) Sequencing chromatogram of genomic DNA of the *XPO1* region around the targeted cysteine codon from homozygous mutant XPO1~C528S~ cells. Mutated codon (528 TGT ➔ TCA) is indicated in bold. The sgRNA sequence of the CRISPR is underlined and the PAM motif is given in magenta.\
(B) Wild-type and mutant XPO1~C258S~ HEK293T cells were transfected with HIV-1 molecular clone NL4-3 and treated with different concentrations of KPT-185. Virus production was analyzed by virus-associated p24 Gag protein in the supernatant. Error bars represent standard deviations, n = 3.](gr3){#f0015}

![XPO1 inhibition by KPT-185 induces selective cytotoxicity, apoptosis and cell cycle arrest in PEL cells.\
(A) PEL cell lines, BC-1, BCBL-1 and JSC-1, and whole PBMC fraction from normal donors were examined for XPO1 expression by western blot.\
(B) Cell viability of BC-1, BCBL-1 and JSC-1 treated cells as measured by MTT-assay, as compared to treated PBMCs as measured by annexin V-PI flow cytometry. Error bars represent standard error of mean, n ≥ 2.\
(C) Detection of apoptosis in BC-1, BCBL-1 and JSC-1 cells as early as 24 h after KPT-185 treatment as measured by annexin V-PI flow cytometry. Error bars represent standard error of mean, n ≥ 2.\
(D) XPO1 inhibition promotes cell death through a caspase-dependent pathway. PEL cells were treated overnight with KPT-185 in the absence or presence of the general caspase inhibitor Q-VD-OPH. Whole cell extracts were assessed for cleavage of PARP and caspase 3 by western blot analyses.\
(E) BC-1, BCBL-1 and JSC-1 cells were treated with different concentrations of KPT-185 and stained with PI (BD Cycletest Plus, BD Biosciences) for cell cycle profiles using flow cytometric analysis. Upon treatment with KPT-185 a clear reduction of the G2/M and S populations is observed while the G0/G1 population increased as well as the subG1 population. Error bars represent standard error of mean, n ≥ 2.](gr4){#f0020}

![KPT-185 increases nuclear p53 levels, decreases XPO1 protein level and affects NF-kB activity.\
(A) Immunostaining of p53 in PEL cells treated overnight with 1 μM KPT-185 shows increase in nuclear p53 levels as compared to vehicle control. See also Figure S3.\
(B) Representative blot and densitometry of p53 expression in nuclear extracts of BC-1, BCBL-1 and JSC-1 cells after treatment with 0.5 or 1 μM KPT-185. Actin was used as a loading control. Results are means ± SEM (n = 3) \* *P* \< 0.05, \*\* *P* \< 0.01 or \*\*\* *P* \< 0.001 *vs.* respective untreated control by paired *t*-test. See also Figure S4 for control of the nuclear extracts.\
(C) KPT-185 enhances nuclear function of p53. Densitometry of the p53 target gene p21 expression in nuclear extracts of PEL cells after treatment with 0.5 or 1 μM KPT-185 for 8 h. Actin was used as a loading control. Results are means ± SEM (n = 2).\
(D) BC-1, BCBL-1 and JSC-1 were transfected either with a 6 × NF-κB-Luc reporter plasmid or a control CMV-Luc plasmid and treated with 0.5 or 1 μM KPT-185. Luciferase activity was measured and signal from NF-κB-Luc reporter was normalized according to the signal from the control CMV-Luc reporter. Results are means ± SEM (n = 3) \* *P* \< 0.05, \*\* *P* \< 0.01 or \*\*\* *P* \< 0.001 *vs.* respective untreated control by paired *t*-test.\
(E) Blot and densitometry of XIAP expression in whole extracts of BC-1, BCBL-1 and JSC-1 cells after treatment with 0.5 or 1 μM KPT-185. Actin was used as a loading control. Results are means ± SEM (n = 3) \* *P* \< 0.05, \*\* *P* \< 0.01 or \*\*\* *P* \< 0.001 *vs.* respective untreated control by paired *t*-test.\
(F) Blot and densitometry of IκB-α expression in nuclear extracts of BC-1, BCBL-1 and JSC-1 cells after treatment with 0.5 or 1 μM KPT-185. Actin was used as a loading control.\
Results are means ± SEM (n = 5) \* *P* \< 0.05, \*\* *P* \< 0.01 *vs.* respective untreated control by paired *t*-test.](gr5){#f0025}

![Anti-PEL activity of KPT-330 *in vivo*: growth curves of KPT-330 and vehicle control-treated BC-1 xenografts.\
(A) Tumor growth was determined in athymic nude mice bearing a BC-1 xenograft that received KPT-330 or vehicle treatment *per os* twice a week. Data were collected from two independent experiments including a total of 11 mice per group. Tumors were measured by means of a digital caliper in two directions and the formula V = (length × width^2^) / 2 was used to calculate the tumor volume. At week 3, animals treated with vehicle control had to be euthanized because of ethical reasons.\
(B) Body weight measurements of treated and vehicle control mice.\
(C) Tumors from placebo and KPT-330 treated mice were processed for histological examination. In both groups, tumors with a volume ≥ 1000 mm^3^ presented areas ≥ 25 mitosis/mm^2^, and \< 5% p53^+^cells (upper panel). The smaller size tumors from KPT-330 treated mice presented only areas of 1 mitosis/mm^2^ and \> 10% p53^+^ cells (lower panel).](gr6){#f0030}

###### 

Broad-spectrum anti-HIV activity of KPT-185 against clinical isolates from different subtypes of group M.

            EC~50~ (nM)                                                                     
  --------- ------------- ------------ ------------ ------------ ------------ ------------- ------------
  KPT-185   55.2 ± 6.6    34.8 ± 3.6   42.9 ± 8.7   38.1 ± 8.5   52.8 ± 9.2   30.3 ± 11.1   37.1 ± 9.6

[^1]: Equal contributing authors.
